Details
Stereochemistry | MIXED |
Molecular Formula | C22H32N2O6 |
Molecular Weight | 420.4993 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(CNCCCCCCNCC(O)C1=CC(O)=C(O)C=C1)C2=CC=C(O)C(O)=C2
InChI
InChIKey=OXLZNBCNGJWPRV-UHFFFAOYSA-N
InChI=1S/C22H32N2O6/c25-17-7-5-15(11-19(17)27)21(29)13-23-9-3-1-2-4-10-24-14-22(30)16-6-8-18(26)20(28)12-16/h5-8,11-12,21-30H,1-4,9-10,13-14H2
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/195789Curator's Comment: description was created based on several sources, including, http://home.intekom.com/pharm/intramed/ipradinf.html
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789
Curator's Comment: description was created based on several sources, including, http://home.intekom.com/pharm/intramed/ipradinf.html
Hexoprenaline is a selective beta2-adrenoreceptor agonist indicated for use in the treatment of bronchospasm associated with obstructive airways diseases, including asthma, bronchitis and emphysema. In many countries the drug is used as tocolytic agent (under the trade name gynipral).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789 |
Palliative | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789 |
Primary | Unknown Approved UseUnknown |
||
Preventing | GYNIPRAL Approved UseGynipral prevents threatened abortion with premature labour. |
PubMed
Title | Date | PubMed |
---|---|---|
Hexoprenaline: a review of its pharmacological properties and therapeutic efficacy with particular reference to asthma. | 1977 Jul |
|
[Tocolysis with hexoprenalin and salbutamol in a clinical comparison]. | 1983 Mar |
|
A comparison of the relative toxicities of beta-sympathomimetic tocolytic agents. | 1985 Oct |
|
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. | 2001 |
|
The effects of fetal breathing movements on the utero-fetal-placental circulation. | 2001 Jan |
|
A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. | 2004 Apr |
|
[Comparison of the cost of treatment of premature labor with atosiban or beta-sympathomimetics from the perspective of the health care payer--a pharmacoeconomic model]. | 2004 Mar |
|
Betamimetics for inhibiting preterm labour. | 2004 Oct 18 |
|
Beta 2-agonist treatment enhances uterine oxytocin receptor mRNA expression in pregnant rats. | 2004 Sep |
|
Arg16 homozygosity of the beta2-adrenergic receptor improves the outcome after beta2-agonist tocolysis for preterm labor. | 2005 Dec |
|
Circulatory corticotropin-releasing hormone mRNA concentrations are increased in women with preterm delivery but not in those who respond to tocolytic treatment. | 2005 Mar |
|
Flow injection potentiometric assay of hexoprenaline in its pure state, pharmaceutical preparations, and biological samples. | 2008 |
|
Treatment of pregnant women with a betamimetic and verapamil increases the micronuclei frequency in umbilical cord blood lymphocytes. | 2008 Aug |
|
Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation. | 2009 Jun 19 |
|
Management of foetal asphyxia by intrauterine foetal resuscitation. | 2010 Sep |
|
Dependence of the lymphocyte proliferative response on the endogenous cortisol level and sensitivity to β-adrenergic regulation in vitro in the early period of penetrating eye injury. | 2010 Sep-Oct |
Sample Use Guides
Hexoprenaline can be given by metered aerosol in doses of 200 to 400μg, up to 5 times daily (in asthma), or as an infusion of 0,30 ug and 0,45 ug per minute or as 1-2 tablets q.i.d (0.5 mg per tablet) (maintenance dose in premature labour).
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R03AC06
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
||
|
WHO-ATC |
R03CC05
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
||
|
WHO-VATC |
QR03CC05
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
||
|
WHO-VATC |
QR03AC06
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2650
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | |||
|
100000083961
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | |||
|
DTXSID7048322
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | |||
|
HEXOPRENALINE
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | |||
|
CHEMBL1589896
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | |||
|
5307
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | RxNorm | ||
|
G9L6B3W684
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | |||
|
DB08957
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | |||
|
D006594
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | |||
|
C170044
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | |||
|
3215-70-1
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | |||
|
3609
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | |||
|
m6013
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB08041MIG
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY | |||
|
1372
Created by
admin on Fri Dec 15 18:36:16 GMT 2023 , Edited by admin on Fri Dec 15 18:36:16 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)